Hyattsville Rehab Center, Llc | |
7411 Riggs Rd Ste 219, Adelphi, MD 20783-4246 | |
(703) 214-1000 | |
Not Available |
Full Name | Hyattsville Rehab Center, Llc |
---|---|
Type | Facility |
Speciality | Clinic/center - Pain |
Location | 7411 Riggs Rd Ste 219, Adelphi, Maryland |
Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1639733348 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
111N00000X | Chiropractor | (* (Not Available)) | Secondary |
261QP3300X | Clinic/center - Pain | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Hyattsville Rehab Center, Llc 7411 Riggs Rd Ste 219, Adelphi, MD 20783-4246 Ph: () - | Hyattsville Rehab Center, Llc 7411 Riggs Rd Ste 219, Adelphi, MD 20783-4246 Ph: (703) 214-1000 |
News Archive
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, today announced the release of beta version of USP Spectral Library™ powered by Bio Rad's KnowItAll® software technology platform for spectral analysis, identification, search, data management, and reporting.
Britain's Department of Health has announced a review of the Medical Training Application Service for junior doctors.
Contrary to prevailing assumptions, children are more vulnerable to the harmful effects of lead exposure at the age of 6 than they are in early childhood, according to a Cincinnati Children's Hospital Medical Center study to be presented May 4 at the annual meeting of the Pediatric Academic Societies in Honolulu.
Why does exposure to rhythmic stimulation at certain frequencies facilitate the occurrence of epileptic seizures? In 1997, flickering patterns in an episode of the series Pokémon triggered epileptic seizures in nearly 700 Japanese children.
Repros Therapeutics Inc. today reported it has received Institutional Review Board (IRB) approval to commence the Phase IIb study of Androxal® in men with secondary hypogonadism. The Company has submitted the protocol for FDA comment and plans to begin enrolling subjects in January. Depending on the rate of subject enrollment, Repros hopes to have the study completed before the end of 2011.
› Verified 4 days ago